Barbara Kosacz is the international head of the Cooley LLP’s life sciences practice and serves on Cooley’s management committee. She has over 25 years of experience in counseling clients in the life sciences arena. Her clients range from early-stage startups to larger public companies, and include venture funds, investment banks, and non-profit institutions. Kosacz is known for working closely with her clients as an integral part of the management team in setting strategic direction, and structuring and negotiating mission-critical transactions. Her combination of business and legal experience covers the full spectrum of transactions and issues facing life sciences and other healthcare companies.
Kosacz advises clients on a variety of legal and business issues. Her particular expertise is in highly negotiated transactions, from complex strategic partnering transactions to mergers and acquisitions. She also represents companies and investors in private financings, strategic investments, spin-outs, carve-outs, and public offerings.
Kosacz has served as a member of the BIO Emerging Companies’ Section Governing Board and has been a speaker at multiple life sciences-related conferences (Allicense; BIO, BIO Europe; BIO CEO & Investor Conference; BioEquity Europe; BIO Annual Meetings; etc.), as well as guest lecturer at University of California, Berkeley and Stanford University on biotechnology law, biotech business models, corporate partnering negotiations and deal structures, and bioethics.